​

Tempest Therapeutics Stock (NASDAQ:TPST)

ForecastOwnershipFinancialsChart
Tempest Therapeutics by TradingView

Previous Close

$2.40

52W Range

$2.12 - $12.23

50D Avg

$2.57

200D Avg

$6.52

Market Cap

$10.17M

Avg Vol (3M)

$106.02K

Beta

-2.18

Div Yield

-

TPST Company Profile

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

24

IPO Date

Nov 12, 2012

Website

TPST Performance

TPST Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-29.16M$-34.64M
Net Income$-41.84M$-29.49M$-36.78M
EBITDA-$-28.78M$-32.28M
Basic EPS$-1.50$-1.91$-3.18
Diluted EPS$-1.50$-1.91$-3.18

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
KZRKezar Life Sciences, Inc.
MRSNMersana Therapeutics, Inc.
INMBINmune Bio, Inc.
OKUROnKure Therapeutics, Inc.
FGENFibroGen, Inc.
BRNSBarinthus Biotherapeutics plc
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
ALGSAligos Therapeutics, Inc.